Pharmaceutical company AstraZeneca has been able to use “outdated” data in clinical studies in the United States for its covid vaccine. This is according to a press release distributed by the National Institute for Allergies and Infectious Diseases (NIAID) on Monday evening, the American institute that supervises clinical tests.
–
“There is concern that AstraZeneca could use outdated information in that US study. This may have led to an incomplete estimate of the effectiveness of the vaccine, ”NIAID writes.
“We call on the company to work with the Data and Safety Monitoring Board (DSMB) to verify the effectiveness of the data and ensure that the most accurate, recent and effective data is available as soon as possible”, writes NIAID.
AstraZeneca defended its vaccine on Monday, which has raised doubts in Europe. The company stated that it is 80 percent effective against Covid in the elderly. AstraZeneca also stated that there was no increased risk of blood clots after the phase 3 study, with 32,449 participants, in the United States.
Across the population, the AstraZeneca vaccine is 79 percent effective against symptomatic Covid-19. It is 100 percent effective against severe forms of the disease and hospitalization, AstraZeneca said after the clinical studies.
Several European countries suspended vaccinations with the AstraZeneca vaccine this month, because it could cause thromboses. But on Thursday, the European Medicines Agency concluded that the vaccine was “safe and effective,” prompting those countries to retrace their steps.
– .
